Biomarin Pharmaceutical - Registered Shares Receivables

The latest receivables for BMRN is $900M as of March 2026. That compares with $740M in the prior-year period — up 22.3% year over year. Investors often review this figure alongside Biomarin Pharmaceutical - Registered Shares's historical trend and sector peers before judging valuation or financial health.

Over the past year, BMRN's receivables moved from $740M to $900M — a 22.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Biomarin Pharmaceutical - Registered Shares's operating scale or balance-sheet position.

A receivables figure of $900M for BMRN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BMRN's receivables ($900M), review year-over-year change from $740M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Biomarin Pharmaceutical - Registered Shares's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.